metricas
covid
Annals of Hepatology Most often read
Journal Information

Most often read

1735
First Latin American consensus on the treatment and prophylaxis of hepatic encephalopathy
Fátima Higuera-de-la-Tijera, Mario Reis Alvares-da-Silva, Graciela Elia Castro-Narro, Josué Barahona-Garrido, Enrique Carrera-Estupiñán, Jorge Garavito-Rentería, Héctor Adolfo Henríquez-Meléndez, Geovanny Hernández-Cely, ... José Antonio Velarde-Ruiz Velasco
Ann Hepatol. 2026;31:102142
1735
Full text access
1339
Comparisons of global incidence and risk factor profiles of hepatocellular carcinoma and intrahepatic cholangiocarcinoma
Tianhao Wu, Mingyi Du, Tiejun Zhang, Xingdong Chen, Zhenqiu Liu
Ann Hepatol. 2026;31:102139
1339
Full text access
1202
Noninvasive elastography-based assessment of liver fibrosis in primary biliary cholangitis
Xiaohui Ye, Lingling He, Caihong Deng, Junru Yang, Ping Li, Hongshan Wei
Ann Hepatol. 2026;31:102150
1202
Full text access
1135
Diagnosis of metabolic dysfunction-associated steatotic liver disease by triglyceride glucose-body mass index: A systematic review and meta-analysis
Kexin Du, Yafang Huang, Yanhui Yu, Jianrong Guo, Jianmei Feng, Feng Jiang
Ann Hepatol. 2026;31:102122
1135
Full text access
1046
Pruritus in primary biliary cholangitis: insights from the German PBC registry across secondary and tertiary care
Toni Herta, Annegret Franke, Tobias Müller, Kerstin Stein, Heike Bantel, Rainer Günther, Gerald Denk, Philipp A. Reuken, ... Andreas E. Kremer
Ann Hepatol. 2026;31:102140
1046
Full text access
948
Epidemiology and etiologic trends of hepatocellular carcinoma in cirrhotic patients in Mexico: a multicenter retrospective study (2018–2024)
Nahum Méndez-Sánchez, Mariana M. Ramírez-Mejía, Carlos Cortez-Hernández, Elianee M. Tovar-Bojorquez, Raúl Contreras-Omaña, Juan D. Monsiváis-Morales, Jacqueline Cordova-Gallardo, Mauricio Castillo-Barradas, ... Heriberto Rodríguez-Hernández
Ann Hepatol. 2026;31:102131
948
Full text access
940
Prospective surveillance reveals high rates of antimicrobial resistance in urinary tract infections among patients with cirrhosis.
Carolina Vazquez, Gonzalo Gómez Perdiguero, Esteban González Ballerga, Ilse Pardo Ivirico, Camila M. Briz, Agustín Di Santo, Maria D. Murga, Ana Palazzo, ... Sebastián Marciano
Ann Hepatol. 2026;31:102135
940
Full text access
770
Bidirectional association between chronic liver disease and chronic kidney disease: a longitudinal study based on CHARLS 2011–2020 data
Yuan He, Fan Zhang, Zixuan Zhang, Xianwen Zhang, Yifei Zhong
Ann Hepatol. 2026;31:102115
770
Full text access
709
Limitations of MELD and MELD 3.0 for prognostication in patients with cirrhosis hospitalized with acute decompensation: an analysis of the ATTIRE trial
Nikolaj Torp, Nick Freemantle, Mads Israelsen, Aleksander Krag, Alastair O’Brien
Ann Hepatol. 2026;31:102137
709
Full text access
697
Prognosis of hepatocellular carcinoma in the French overseas territories and comparison with a tertiary center in mainland France
Alolia Aboikoni, Manon Allaire, Dominique Louvel, Marthe Alogo A. Nwatsok, Paul Ngock Dime, Ala Ouni, Larissa Tangan, Magaly Zappa, ... Moana Gelu-Simeon
Ann Hepatol. 2026;31:102120
697
Full text access
696
Long-term albumin treatment for decompensated cirrhosis in Italy: A propensity score-matched, retrospective, real-world chart analysis
Wim Laleman, Jonel Trebicka, Alastair O’Brien, Giacomo Zaccherini, Paolo Caraceni, Joana F. Rodrigues, Xiang Zhang, Maebh Kelly, ... Paolo Angeli
Ann Hepatol. 2026;31:102153
696
Full text access
600
Serum IL-6 is a prognostic biomarker for advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab
Lorenz Kocheise, Jan Kempski, Yunhe Tang, Lorenz Balcar, Victoria Berger, Miriam Tomczak, Joao Gorgulho, Ramsha Masood, ... Kornelius Schulze
Ann Hepatol. 2026;31:102138
600
Full text access
575
Trends and health inequalities of hepatitis virus-associated liver cancer mortality during 1990–2050
Yujiao Deng, Jingyue Tan, Jian Zu, Zixuan Xing, Zhanpeng Yang, Yue Zhang, Yajing Bo, Xu Gao, ... Yang Yang
Ann Hepatol. 2026;31:102144
575
Full text access
574
Impact of neohepatic albumin-bilirubin scores on renal outcomes following living donor liver transplantation: a propensity score analysis
Hye-Won Jeong, Hye-Mee Kwon, Sung-Hoon Kim, Seong-Mi Yang, In-Gu Jun, Jun-Gol Song, Gyu-Sam Hwang
Ann Hepatol. 2026;31:102111
574
Full text access
551
Aspartate aminotransferase‑to‑platelet ratio index (APRI) reliably excludes advanced fibrosis and cirrhosis in treated autoimmune hepatitis
Martine A.M.C. Baven-Pronk, Camiel J.M. Marijnissen, Maaike Biewenga, Albert F. Stättermayer, Maarten E. Tushuizen, Bart van Hoek
Ann Hepatol. 2026;31:102146
551
Full text access
402
Antibiotic consumption, genetic risk and incidence of metabolic dysfunction-associated steatotic liver disease: a prospective cohort study
Ziming Zheng, Yumei Huang, Jijuan Zhang, Jinchi Xie, An Pan, Yunfei Liao, Yu Zhang
Ann Hepatol. 2026;31:102136
402
Full text access
353
Piloting eLearning initiatives: Computer-based training and telementoring for viral hepatitis care in public primary care setting
Janus P. Ong, Geohari Hamoy, Eric David B. Ornos, Vanessa Co-Tanco, Joy Gillera, Jhunnel Macalanda, Jae-Ann Sumalo
Ann Hepatol. 2026;31:102133
353
Full text access
240
Non-hepatic cancers in alcohol-related liver disease with insights for clinical management
Weiyi Jiang, Qianqian Yin, Mengyi Hu, Tingsu Zhang
Ann Hepatol. 2026;31:102152
240
Full text access
142
Beyond the association: towards an integrated hepato–renal approach
Juanita Pérez-Escobar, Ricardo Ivan Velazquez-Silva, Paulina Carpinteyro-Espin, José Carlos Gasca-Aldama
Ann Hepatol. 2026;31:102155
142
Full text access